ATC Code G04CB02
Formula C27H30F6N2O2
Molar Mass (g·mol−1) 528,53
Physical State solid
Melting Point (°C) 242–25
CAS Number 164656-23-9
PUB Number 6918296
Drugbank ID DB01126
Solubility practically insoluble in water


Dutasteride is a drug used to treat the symptoms of benign prostatic hyperplasia (BPH) in men. It is also used for hair loss in men and as part of hormone therapy in transgender women. It is usually taken orally and is available in capsule form.

It was first approved by the U.S. Food and Drug Administration (FDA) in 2001 and has since been widely used due to its good efficacy.


Pharmacodynamics and mechanism of action

BPH is a disease in which the prostate gland enlarges, causing symptoms such as frequent urination and difficulty urinating. Dutasteride belongs to the class of 5-alpha-reductase inhibitors and works by inhibiting the activity of the enzyme 5-alpha-reductase. This enzyme is responsible for converting testosterone into dihydrotestosterone (DHT), a hormone responsible for enlargement of the prostate. Inhibition of this enzyme decreases the formation of DHT, resulting in a reduction in the size of the prostate and significantly improving symptoms.


Dutasteride is rapidly and completely absorbed after oral administration, with maximum plasma concentrations reached within 2 to 3 hours. Dutasteride is approximately 99% bound to albumin. Dutasteride undergoes extensive hepatic metabolism mediated by the CYP3A4 and CYP3A5 enzymes and is excreted primarily in the feces. The plasma half-life is approximately 4-5 weeks.


Side effects

The most common side effects include:

  • decreased libido
  • Ejaculation problems
  • Breast tenderness or enlargement.

More serious side effects may include allergic reactions, liver damage, and increased risk of prostate cancer.

Contraindications and precautions

Dutasteride is contraindicated in patients allergic to the drug and in women who are pregnant or breastfeeding. In addition, dutasteride should not be taken by patients with severe liver dysfunction.

Markus Falkenstätter

Markus Falkenstätter

Markus Falkenstätter ist Autor zu pharmazeutischen Themen in der Medizin-Redaktion von Medikamio. Er befindet sich im letzten Semester seines Pharmaziestudiums an der Universität Wien und liebt das wissenschaftliche Arbeiten im Bereich der Naturwissenschaften.

Mag. pharm Stefanie Lehenauer

Mag. pharm Stefanie Lehenauer

Stefanie Lehenauer ist seit 2020 freie Autorin bei Medikamio und studierte Pharmazie an der Universität Wien. Sie arbeitet als Apothekerin in Wien und ihre Leidenschaft sind pflanzliche Arzneimittel und deren Wirkung.

Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über Medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.